4.6 Article

miRNa signature in small extracellular vesicles and their association with platinum resistance and cancer recurrence in ovarian cancer

出版社

ELSEVIER
DOI: 10.1016/j.nano.2020.102207

关键词

Ovarian cancer; Exosomes; Nanovesicles; miRNAs; Biomarkers

资金

  1. King Saud University (K.S.A), Riyadh
  2. Lions Medical Research Foundation
  3. UQ-Ochsner Seed Fund for Collaborative Research, The University of Queensland
  4. Faculty of MedicineM + BS Emerging LeadersMedical Research Grant
  5. Fondo Nacional de Desarrollo Cientifico y Tecnologico [FONDECYT 1170809]
  6. Ovarian Cancer Research Foundation

向作者/读者索取更多资源

Carboplatin, administered as a single drug or in combination with paclitaxel, is the standard chemotherapy treatment for patients with ovarian cancer (OVCA). Recent evidence suggests that miRNAs associated with small extracellular vesicles (sEVs) participate in the development of chemoresistance. We studied the effect of carboplatin in a heterogeneity population of OVCA cells and their derived sEVs to identify mechanisms associated with chemoresistance. sEVs were quantified using an engineered superparamagnetic material, gold-loaded ferric oxide nanotubes and a screen-printed electrode. miR-21-3p, miR-21-5p, and miR-891-5p are enriched in sEVs, and they contribute to carboplatin resistance in OVCA. Using a quantitative MS/MS, miR-21-5p activates glycolysis and increases the expression of ATP-binding cassette family and a detoxification enzyme. miR-21-3p and miR-891-5p increase the expression of proteins involved in DNA repair mechanisms. Interestingly, the levels of miR-8915p within sEVs are significantly higher in patients at risk of ovarian cancer relapse. Identification of miRNAs in sEVs also provides the opportunity to track them in biological fluids to potentially determine patient response to chemotherapy. (C) 2020 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据